Abstract
AbstractThis study aimed to investigate the effect of orbital wall decompression surgery and reduction of proptosis on the choroidal vascularity index (CVI) and subfoveal choroidal thickness (SFCT) in patients with thyroid eye disease (TED). Fifty-one eyes from 38 patients with controlled TED and proptosis were enrolled in this study. The majority of the patients (50.9%) had a clinical activity score (CAS) of zero, and none had a CAS greater than 2. The patients underwent a complete baseline ophthalmologic examination, and their choroidal profile alterations were monitored using enhanced depth imaging optical coherence tomography (EDI-OCT) before and during the three months after surgery. Changes in SFCT, luminance area (LA), total choroidal area (TCA), and the choroidal vascularity index (CVI) were measured as the ratio of LA to TCA in EDI-OCT images. The participants had an average age of 46.47 years, and 22 were female (57.9%). The SFCT of the patients exhibited a significant reduction over the follow-up period, decreasing from 388 ± 103 to 355 ± 95 µm in the first month (p < 0.001) and further decreasing to 342 ± 109 µm by the third month compared to baseline (p < 0.001). The CVI exhibited a drop from 0.685 ± 0.037 at baseline to 0.682 ± 0.035 and 0.675 ± 0.030 at 1 and 3 months post-surgery, respectively. However, these changes were not statistically significant, indicating comparable decreases in both LA and TCA. There was a significant correlation between improved proptosis and reduction in SFCT (p < 0.001) but not with CVI (p = 0.171). In conclusion, during the three months of follow-up following orbital wall decompression, CVI did not change, while SFCT reduced significantly. Additionally, SFCT was significantly correlated with proptosis reduction, whereas CVI was not.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Douglas, R. S. & Gupta, S. The pathophysiology of thyroid eye disease: Implications for immunotherapy. Curr. Opin. Ophthalmol. 22, 385–390 (2011).
2. Gibson, A., Kothapudi, V. N. & Czyz, C. N. Graves disease orbital decompression. In StatPearls (StatPearls PublishingCopyright © 2023, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Venkata Neelima Kothapudi declares no relevant financial relationships with ineligible companies. Disclosure: Craig Czyz declares no relevant financial relationships with ineligible companies, 2023).
3. Bartalena, L. Diagnosis and management of Graves disease: A global overview. Nat. Rev. Endocrinol. 9, 724–734 (2013).
4. Perros, P., Crombie, A., Matthews, J. & Kendall-Taylor, P. Age and gender influence the severity of thyroid-associated ophthalmopathy: A study of 101 patients attending a combined thyroid-eye clinic. Clin. Endocrinol. 38, 367–372 (1993).
5. Khong, J. J. et al. Risk factors for Graves’ orbitopathy; The Australian thyroid-associated orbitopathy research (ATOR) study. J. Clin. Endocrinol. Metab. 101, 2711–2720 (2016).